Saturday 17 October 2026
Export CAMP’s income statement to Excel — free account
CAMP4 Therapeutics Corporation
CAMP Healthcare Biotechnology
CAMP4 Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, up 436.5% from fiscal 2024. In the quarter to June 2026, revenue grew 18.8%, EPS grew 6.45% and free cash flow fell 23.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.17
0.28
−8.12%
Follow CAMP
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | (4.18) | (2.32) |
P/S ratio |
— | 0.00 | 0.00 | 53.24 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (9.55) | (4.24) | (4.88) |
P/Operating CF |
— | (0.62) | (2.17) | 29.59 |
P/B ratio |
— | 0.00 | 0.39 | 3.90 |
Price to Tangible BV |
— | 0.00 | 0.39 | 3.90 |
EV/Sales |
— | 0.00 | 0.00 | 21.56 |
EV/EBITDA |
— | 0.00 | 0.76 | 0.00 |
EV/Operating CF |
— | (0.08) | 0.87 | (2.55) |
EV/FCF |
— | (0.08) | 0.86 | (2.53) |
Quick Ratio |
10.47 | 4.92 | 6.67 | 7.15 |
Current Ratio |
10.62 | 5.13 | 6.92 | 7.35 |
Net Debt/EBITDA |
1.88 | 0.76 | 1.24 | 2.18 |
Debt/Assets |
0.14% | 0.27% | 0.09% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.01 | 0.04 |
Operating CF/Net income |
0.87 | 0.90 | 0.88 | 0.37 |
Capex/Depreciation |
(4.58) | (0.40) | (0.26) | (0.15) |
| 0.00% | 48.98% | 170.97% | (145.07%) | |
| 0.00% | (62.59%) | (77.73%) | (82.00%) | |
ROIC |
(1,790.30%) | (17,526.69%) | 0.00% | 0.00% |
Return on Tangible Assets |
(53.82%) | (133.21%) | (85.40%) | (79.67%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 11,604.57% | 5,953.53% | 1,092.11% |
Selling, General and Administrative Expense of Revenue |
0.00% | 3,318.00% | 2,288.80% | 496.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 830.57% | 618.40% | 114.29% |
Graham Net Nets |
— | (2.12) | 2.09 | 0.24 |
Graham Number |
— | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (988.52%) | (211.56%) | (43.39%) |
Free Cash Flow Yield |
— | (777.83%) | (187.90%) | (16.00%) |
Revenue per Share |
0.00 | 0.89 | 0.14 | 0.12 |
Operating CF per Share |
(123.42) | (111.78) | (9.71) | (0.97) |
Capex per Share |
(12.89) | (1.72) | (0.09) | (0.01) |
Free Cash Flow per Share |
(136.30) | (113.50) | (9.81) | (0.98) |
Cash per Share |
266.38 | 97.16 | 13.65 | 3.65 |
Shareholders Equity per Share |
270.94 | 97.26 | 13.46 | 1.57 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
270.94 | 97.26 | 13.46 | 1.57 |
Free Cash Flow |
(42.57) | (44.83) | (46.00) | (29.80) |
Working Capital |
76.46 | 32.21 | 56.79 | 98.58 |
Capital Expenditures |
(4.02) | (0.68) | (0.44) | (0.24) |
Net Current Asset Value |
66.44 | 23.48 | 51.22 | 43.99 |
EV/EBIT |
— | 0.00 | 0.74 | 0.00 |
Capex to Sales |
0.00 | 1.94 | 0.68 | 0.07 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.16 | 0.35 | 0.44 | 0.70 |
Cash ROIC |
(25.35%) | (58.27%) | (36.15%) | (18.79%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 1.60 | 1.13 | 0.70 |
Average Assets |
— | 78.75 | 66.63 | 98.06 |
Average Common Equity |
— | (100.63) | (30.29) | 55.42 |
Columns are period end dates